<DOC>
	<DOCNO>NCT02876835</DOCNO>
	<brief_summary>The purpose multi-center event-driven study non-dialysis ( ND ) participant anemia associate chronic kidney disease ( CKD ) evaluate safety efficacy daprodustat compare darbepoetin alfa .</brief_summary>
	<brief_title>Anemia Studies Chronic Kidney Disease : Erythropoiesis Via Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis ( ASCEND-ND )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Prolyl-Hydroxylase Inhibitors</mesh_term>
	<criteria>Age : 18 99 year age ( inclusive ) . CKD stage : Kidney Disease Outcomes Quality Initiative ( KDOQI ) CKD stag 3 , 4 , 5 define electronic estimate glomerular filtration rate ( eGFR ) use CKD Epidemiology Collaboration ( CKDEPI ) formula . Erythropoietinstimulating agent ( ESAs ) /Hgb : Group 1 ( use ESAs ) : No ESA use within 6 week prior screen ESA use screen randomization ( Day 1 ) . Hgb concentration : On randomization ( Day 1 ) : Hgb 8 10 gram ( g ) /deciliter ( dL ) . Group 2 ( ESA user ) : Use approve ESA 6 week prior screen continue screening randomization . Hgb concentration : On randomization ( Day 1 ) : Hgb 8 11 g/dL receive least minimum ESA dose . Compliance placebo [ randomization ( Day 1 ) ] : &gt; =80 % &lt; =120 % compliance placebo runin period . Informed consent : capable give sign informed consent include compliance requirement restriction list consent form protocol . Dialysis : On dialysis clinical evidence impend need initiate dialysis within 90 day study start ( Day 1 ) . Ferritin : &lt; =100 nanogram ( ng ) /milliliter ( mL ) ( &lt; =100 micrograms/liter [ L ] ) screening . Transferrin saturation ( TSAT ) ( screen ) : &lt; =20 % . Aplasias : History bone marrow aplasia pure red cell aplasia . Other cause anemia : Pernicious anemia , thalassemia major , sickle cell disease myelodysplastic syndrome . Gastrointestinal ( GI ) bleeding : Evidence actively bleed gastric , duodenal , esophageal ulcer disease clinically significant GI bleeding &lt; =4 week prior screen randomization ( Day 1 ) . MI acute coronary syndrome : &lt; =4 week prior screen randomization ( Day 1 ) . Stroke transient ischemic attack : &lt; =4 week prior screen randomization ( Day 1 ) . Heart failure ( HF ) : Chronic Class IV HF , define New York Heart Association ( NYHA ) functional classification system . Current uncontrolled hypertension : Current uncontrolled hypertension determine investigator would contraindicate use recombinant human erythropoietin ( rhEPO ) . Bazett 's correct QT interval ( QTcB ) ( Day 1 ) : QTcB &gt; 500 millisecond ( msec ) , QTcB &gt; 530 msec subject bundle branch block . There QT Interval Corrected Heart Rate ( QTc ) exclusion subject predominantly pace rhythm . Alanine transaminase ( ALT ) : &gt; 2x upper limit normal ( ULN ) screening . Bilirubin : &gt; 1.5xULN screening . Current unstable liver biliary disease per investigator assessment , generally define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , esophageal gastric varix , persistent jaundice , cirrhosis . Malignancy : History malignancy within 2 year prior screen randomization ( Day 1 ) currently receive treatment cancer , complex kidney cyst ( example [ e.g . ] Bosniak Category II F , III IV ) &gt; 3 centimeter ( cm ) ; exception localize squamous cell basal cell carcinoma skin definitively treat &gt; =4 week prior screen . Severe allergic reaction : History severe allergic anaphylactic reaction hypersensitivity excipients investigational product , darbepoetin alfa . Drugs supplement : Use strong inhibitor Cytochrome P4502C8 ( CYP2C8 ) ( e.g. , gemfibrozil ) strong inducer CYP2C8 ( e.g. , rifampin/rifampicin ) . Prior investigational product exposure : Use investigational agent &lt; =30 day within five half live investigational agent ( whichever longer ) prior screen . Prior treatment daprodustat : Any prior treatment daprodustat treatment duration &gt; 30 day . Females : Subject pregnant [ confirm positive urine human chorionic gonadotrophin ( hCG ) test female reproductive potential ( FRP ) ] , subject breastfeeding , subject reproductive potential agree follow one contraceptive option list List Highly Effective Methods Avoiding Pregnancy . Other Conditions : Any condition , clinical laboratory abnormality , examination find investigator considers would put subject unacceptable risk , may affect study compliance ( e.g. , intolerance darbepoetin alfa ) prevent understand aim investigational procedure possible consequence study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hemoglobin</keyword>
	<keyword>anemia</keyword>
	<keyword>non-dialysis</keyword>
	<keyword>GSK1278863</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>daprodustat</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>